Wall Street brokerages expect that OncoSec Medical Inc (NASDAQ:ONCS) will announce ($0.18) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for OncoSec Medical’s earnings. OncoSec Medical posted earnings per share of ($0.24) during the same quarter last year, which would suggest a positive year over year growth rate of 25%. The company is expected to announce its next quarterly earnings results on Friday, March 8th.

On average, analysts expect that OncoSec Medical will report full-year earnings of ($0.70) per share for the current year, with EPS estimates ranging from ($0.74) to ($0.65). For the next financial year, analysts anticipate that the company will report earnings of ($0.84) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow OncoSec Medical.

OncoSec Medical (NASDAQ:ONCS) last issued its quarterly earnings data on Friday, December 14th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06.

A number of research analysts recently weighed in on the company. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of OncoSec Medical in a research note on Monday, October 15th. HC Wainwright assumed coverage on OncoSec Medical in a research note on Tuesday, October 16th. They set a “buy” rating and a $4.00 price target on the stock. Dawson James lowered OncoSec Medical from a “buy” rating to a “neutral” rating in a report on Wednesday, November 7th. Finally, Maxim Group set a $5.00 price objective on OncoSec Medical and gave the stock a “buy” rating in a report on Friday, November 16th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. OncoSec Medical currently has an average rating of “Hold” and a consensus price target of $4.00.

Several large investors have recently bought and sold shares of ONCS. BlackRock Inc. raised its position in shares of OncoSec Medical by 1,303.5% in the second quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after buying an additional 221,916 shares in the last quarter. 683 Capital Management LLC purchased a new stake in OncoSec Medical during the second quarter valued at about $414,000. Finally, Millennium Management LLC raised its position in OncoSec Medical by 19.5% during the second quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock valued at $1,650,000 after purchasing an additional 194,739 shares in the last quarter. Hedge funds and other institutional investors own 11.49% of the company’s stock.

Shares of NASDAQ ONCS traded up $0.02 during trading on Friday, reaching $0.70. The company had a trading volume of 9,300 shares, compared to its average volume of 379,027. OncoSec Medical has a 12 month low of $0.54 and a 12 month high of $2.21.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Recommended Story: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.